Abstract
Background and objectives The LRRK2 p.G2019S Parkinson’s disease (PD) variant is associated with elevated glucocerebrosidase (GCase) activity in peripheral blood. We aimed to evaluate the association of other LRRK2 variants with PD and its association with GCase activity.
Methods LRRK2 and GBA were fully sequenced in 1,123 PD patients and 576 controls from the Columbia and PPMI cohorts, in which GCase activity was measured in dried blood spots by liquid chromatography-tandem mass spectrometry.
Results LRRK2 p.M1646T was associated with increased GCase activity in the Columbia University cohort (β=1.58, p=0.0003), and increased but not significantly in the PPMI cohort (β=0.29, p=0.58). p.M1646T was associated with PD (OR=1.18, 95%CI=1.09-1.28, p=7.33E-05) in 56,306 PD patients and proxy-cases, and 1.4 million controls.
Conclusions Our results suggest that the p.M1646T variant is associated with risk of PD with a small effect and with increased GCase activity in peripheral blood.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada. The Columbia University cohort is supported by the Parkinson’s Foundation, the National Institutes of Health (K02NS080915, and UL1 TR000040) and the Brookdale Foundation. This research was supported in part by the Intramural Research Program of the NIH, National institute on Aging.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review boards approved the study protocols, and informed consent was obtained from all participants before entering the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Relevant conflicts of interest/financial disclosures: SF received consulting fees/honoraria for board membership from Retrophin Inc., Sun Pharma Advanced Research Co., LTD and Kashiv Pharma. CHW received research support from Sanofi, Biogen, Roche, consulting fees/honoraria from Amneal, Adamas, Impel, Kyowa, Mitsubishi, Neurocrine, US World Meds, Acadia, Acorda. RNA received consultation fees from Biogen, Denali, Genzyme/Sanofi and Roche. ZGO received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Ono Therapeutics, Denali and Deerfield. Rest of the authors have nothing to report.
Funding This study was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada. The Columbia University cohort is supported by the Parkinson’s Foundation, the National Institutes of Health (K02NS080915, and UL1 TR000040) and the Brookdale Foundation. This research was supported in part by the Intramural Research Program of the NIH, National institute on Aging.
Data Availability
Code available at https://github.com/gan-orlab/LRRK2_GCase. Part of the data used in the preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database (www.ppmiinfo.org/data). For up-to-date information on the study, visit www.ppmiinfo.org. PPMI a public private partnership is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including (list the full names of all of the PPMI funding partners found at www.ppmiinfo.org/fundingpartners). We would like to thank the 23andMe research team. We would like to also thank all members of the International Parkinson Disease Genomics Consortium (IPDGC). For a complete overview of members, acknowledgements and funding, please see http://pdgenetics.org/partners.
